Aakha Biologics

Executive Summary

Aakha Biologics is a private biotechnology company founded in 2021 and based in Cambridge, MA, focused on developing first-in-class, multi-specific antibodies for solid tumors. The company's modular platform enables the creation of therapeutics that simultaneously block disease-driving pathways and engage optimal immune activation. Incubated at venture studio 82VS and operating in partnership with Alloy Therapeutics, Aakha aims to address high unmet needs in oncology. While still in early stages with no disclosed pipeline or funding, its approach leverages established antibody engineering capabilities and a growing interest in multi-specific biologics.

Upcoming Catalysts (preview)

• Q4 2026IND Application for Lead Program40% success
• Q2 2026Preclinical Data Presentation at Major Oncology Conference70% success